Gilead Sciences and Merck each reported data updates as they push forward novel daily HIV oral therapies while also exploring a longer‑acting weekly pill in partnership, the companies said. Both firms presented findings that advance individual daily compounds through clinical development and highlighted parallel efforts to create more convenient regimens for people living with HIV. The announcements reflect continued investment in oral antiretroviral innovation—optimizing tolerability, resistance profiles and dosing frequency. Industry participants noted that a weekly oral regimen, if proven safe and efficacious, would represent a meaningful adherence and quality‑of‑life improvement versus current daily dosing. Regulators and payers will watch safety and comparative efficacy closely as these programs advance; successful differentiation on dosing frequency and tolerability could reshape competitive dynamics in chronic HIV management.